The global collaboration between Clinigen Group plc and Pharming Group N.V. to provide access to Pharming’s Ruconest (conestat alfa) is now live. The unique access program was initiated by HAEi, the International Patient Organization for C1- Inhibitor Deficiencies.
Ruconest is a recombinant human C1- inhibitor, approved by the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of acute attacks of HAE. The “HAEi GAP” program enables patients in all countries where Ruconest is not commercially available to gain access to the drug through an ethical and regulatory compliant “Named Patient Program” mechanism.
Physicians wishing to request Ruconest through the HAEi GAP program should contact the Clinigen customer services team at email@example.com or on 0044 1283 494340.
“HAEi is committed to securing access to HAE medications for patients across the globe,” said Anthony J. Castaldo, President of HAEi. “We are extremely proud to have established HAEi GAP with our current partners and to be able to announce that, from today, physicians are able to request Ruconest to meet the needs of their patients.”
Simon Estcourt, Managing Director, Managed Access, Clinigen Group said: “We are very pleased to work with Pharming to help HAEi realize their mission to ensure that sufferers of hereditary angioedema worldwide can access this effective and potentially life-saving treatment. The ground-breaking program provides Ruconest to patients in an ethical and compliant way, removing the need and the risk for patients to resort to other less reliable or even illegal sources of the drug.”
Sijmen de Vries, CEO, Pharming said: “As the first pharmaceutical company to partner with HAEi and provide access to Ruconest through HAEi GAP, we are leading the charge to improve the lives of those HAE patients that otherwise would continue suffering from this debilitating and unpredictable disease.”